Moxifloxacin
This broad-spectrum antibiotic belongs to the fluoroquinolone class and is used to treat bacterial infections of the lungs, sinuses, skin, and abdomen. It works by preventing bacteria from replicating their DNA, effectively stopping the infection from spreading.
Molekularmasse
401,4350 g/mol
LogP
0,60
TPSA
82,10 Ų
Lipinski-Regel der Fünf
Bestanden
Therapeutische Bereiche
Arzneimittelklassen
Wirkmechanismus
Fourth-generation fluoroquinolone inhibiting DNA gyrase and topoisomerase IV with enhanced anaerobic activity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Fourth-generation fluoroquinolone inhibiting DNA gyrase and topoisomerase IV with enhanced anaerobic activity.
2D-Struktur
Cite this structure
Embed this structure
SMILES
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12
InChI
InChI=1S/C21H24FN3O4/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28)/t11-,16+/m0/s1
Molecular Formula
C21H24FN3O4
HBD / HBA
2 / 8
Rotierbare Bindungen
4
Schwere Atome
29
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
This broad-spectrum antibiotic belongs to the fluoroquinolone class and is used to treat bacterial infections of the lungs, sinuses, skin, and abdomen. It works by preventing bacteria from replicating their DNA, effectively stopping the infection from spreading.
Fourth-generation fluoroquinolone inhibiting DNA gyrase and topoisomerase IV with enhanced anaerobic activity.
Key pharmacokinetic parameters for Moxifloxacin: Half-life: 12 hours.
Yes, Moxifloxacin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
Related Drugs
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL32. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 152946. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="moxifloxacin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/moxifloxacin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/moxifloxacin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/moxifloxacin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="moxifloxacin"></drugfyi-drug>